Locally advanced HER2 positive breast cancer

HER2 positive accounts for 6-10% of new cases of breast cancer.

Locally advanced breast cancer is generally associated with a poor prognosis and may be inoperable on presentation or require a mastectomy.

Preoperative systemic therapy used to treat subclinical micrometastatic disease and increase the rate of down staging is increasingly used to promote a successful surgical resection.

Preoperative systemic therapy provides information regarding the responsiveness of the tumor to systemic

HER2 amplification or overexpression is present in approximately 20% of early breast cancers and 35% of locally advanced breast cancers, and has been associated with a poor prognosis.

Leave a Reply

Your email address will not be published. Required fields are marked *